Human Papillomavirus Infections Clinical Trial
Official title:
GARDASIL™ Vaccine Impact in Population Study
This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.
Time perspective: The study will be conducted using data collected both retrospectively/concurrently from registries and prospectively by questionnaire survey. Baseline survey data were collected during a prior study from 2004-2005. Safety Monitoring: An expert panel on teratology consisting of one teratologist from each of the participating countries will review all available medical records related to any congenital anomalies to search for any emerging patterns that may be indicative of an association between GARDASIL™ exposure in the mother and the subsequent congenital anomalies in the babies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03610581 -
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
|
Phase 1/Phase 2 | |
| Completed |
NCT02009800 -
ICI-VPH: Impact of HPV Immunisation Schedules Against HPV
|
Phase 3 | |
| Completed |
NCT01717443 -
Genital HPV Infections Before and After Renal Transplantation
|
N/A |